Lunit INSIGHT

Lunit INSIGHT is a Korean medical-AI product family that reads chest X-rays and mammograms to flag suspicious findings for radiologists.

Overview

Lunit is one of Korea’s most successful medical-AI companies, publicly listed and deployed in hospitals and screening programs worldwide. INSIGHT CXR highlights potential abnormalities in chest radiographs — nodules, consolidation, pneumothorax — while INSIGHT MMG marks suspicious regions in mammograms, helping radiologists catch cancers earlier and work faster. Regulatory clearances across multiple markets and published clinical studies make Lunit a reference case for AI-assisted diagnostics.

Key Features

• Chest X-ray analysis flagging key abnormalities with heatmaps
• Mammography AI that marks suspicious lesions for breast screening
• Hospital PACS integration for seamless reading workflows
• Multimarket regulatory clearances and clinical validations
• Population screening support for public health programs
• Continuous model updates backed by research publications

Pricing

Lunit INSIGHT is sold to hospitals, imaging centers and screening programs under enterprise agreements priced per deployment and study volume.

Who Is It For

Radiology departments, national screening programs and teleradiology networks seeking validated AI triage for chest and breast imaging.

Use Cases

Lunit supports radiology workflows where early detection and reading speed directly change patient outcomes.

• Second-reader support for chest X-ray interpretation
• Breast screening programs with suspicious-region marking
• Prioritization of urgent findings in busy reading queues

Getting Started

Institutions work with Lunit’s clinical team to integrate INSIGHT into PACS workflows, validate performance on local populations and train radiologists on the interface.

Results to Expect

Published studies show improved detection rates and faster reading, while hospitals gain a defensible, clinically validated AI layer for screening programs.

Implementation and Support

Hospital rollouts follow a clinical validation path: PACS integration, local accuracy assessment and radiologist training before the AI informs reads. Lunit’s clinical support accompanies each deployment.

Limitations to Keep in Mind

It is decision support, not autonomous diagnosis, and reimbursement and regulatory status differ by market.

What Users Say

Radiologists report catching findings earlier while reading faster — the combination the product promises.

FAQ

Is Lunit INSIGHT free to use?

No. It is a regulated medical device sold commercially; institutions arrange evaluation and deployment through Lunit’s clinical sales team.

Does Lunit offer an API?

Integration is typically through PACS and hospital imaging systems; programmatic deployment options are defined per institutional agreement.

How does Lunit compare to alternatives?

Against global imaging-AI competitors, Lunit pairs strong clinical evidence with a full product line spanning detection and screening, which simplifies procurement for hospitals.